[1] |
WHO. International Statistical Classification of Diseases, 11th Revision (ICD-11). Geneva, Switzerland: World Health Organization. [2021-03-04]. https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/215767047.
|
[2] |
HE A, FELDMAN S R, FLEISCHER AB J R. An assessment of the use of antihistamines in the management of atopic dermatitis[J]. J Am Acad Dermatol, 2018, 79(1): 92-96. doi: 10.1016/j.jaad.2017.12.077
|
[3] |
中华医学会皮肤性病学分会免疫学组. 湿疹诊疗指南(2011年)[J]. 中华皮肤科杂志, 2011, 44(1): 5-6. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYS201230006.htm
|
[4] |
中华医学会皮肤性病学分会. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020, 53(2): 81-88. https://www.cnki.com.cn/Article/CJFDTOTAL-LPFZ202005016.htm
|
[5] |
WOLLENBERG A, BARBAROT S, BIEBER T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part Ⅱ[J]. J Eur Acad Dermatol Venereol, 2018, 32(6): 850-878. doi: 10.1111/jdv.14888
|
[6] |
DIEPGEN T L, ANDERSEN K E, CHOSIDOW O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema-short version[J]. J Dtsch Dermatol Ges, 2015, 13: 77-85. doi: 10.1111/ddg.12510_1
|
[7] |
SIDBURY R, DAVIS D M, COHEN D E, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents[J]. J Am Acad Dermatol, 2014, 71(2): 327-349. doi: 10.1016/j.jaad.2014.03.030
|
[8] |
WOLLENBERG A, ORANJE A, DELEURAN M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients[J]. J Eur Acad Dermatol Venereol, 2016, 30(5): 729-747. doi: 10.1111/jdv.13599
|
[9] |
GALLI E, NERI I, RICCI G, et al. Consensus conference on clinical management of pediatric atopic dermatitis[J]. Ital J Pediatr, 2016, 42: 26. doi: 10.1186/s13052-016-0229-8
|
[10] |
KIM J E, KIM H J, LEW B L, et al. Consensus guidelines for the treatment of atopic dermatitis in Korea (Part Ⅱ): systemic treatment[J]. Ann Dermatol, 2015, 27(5): 578-592. doi: 10.5021/ad.2015.27.5.578
|
[11] |
SAEKI H, NAKAHARA T, TANAKA A, et al. Clinical practice guidelines for the management of atopic dermatitis 2016[J]. J Dermatol, 2016, 43(10): 1117-1145. doi: 10.1111/1346-8138.13392
|
[12] |
GONZÁLEZ-DE-OLANO D, ÁLVAREZ-TWOSE I. Mast cells as key players in allergy and inflammation[J]. J Investig Allergol Clin Immunol, 2018, 28(6): 365-378. doi: 10.18176/jiaci.0327
|
[13] |
THANGAM E B, JEMIMA E A, SINGH H, et al. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets[J]. Front Immunol, 2018, 9: 1873. doi: 10.3389/fimmu.2018.01873
|
[14] |
SILVESTRE M C, SATO M N, REIS V. Innate immunity and effector and regulatory mechanisms involved in allergic contact dermatitis[J]. An Bras Dermatol, 2018, 93(2): 242-250. doi: 10.1590/abd1806-4841.20186340
|
[15] |
GAUDENZIO N, MARICHAL T, GALLI S J, et al. Genetic and imaging approaches reveal pro-inflammatory and immunoregulatory roles of mast cells in contact hypersensitivity[J]. Front Immunol, 2018, 9: 1275. doi: 10.3389/fimmu.2018.01275
|
[16] |
OTSUKA A, NONOMURA Y, KABASHIMA K. Roles of basophils and mast cells in cutaneous inflammation[J]. Semin Immunopathol, 2016, 38(5): 563-570. doi: 10.1007/s00281-016-0570-4
|
[17] |
KINBARA M, BANDO K, SHIRAISHI D, et al. Mast cell histamine-mediated transient inflammation following exposure to nickel promotes nickel allergy in mice[J]. Exp Dermatol, 2016, 25(6): 466-471. doi: 10.1111/exd.12985
|
[18] |
MUROTA H, KATAYAMA I. Assessment of antihistamines in the treatment of skin allergies[J]. Curr Opin Allergy Clin Immunol, 2011, 11(5): 428-437. doi: 10.1097/ACI.0b013e32834a96e9
|
[19] |
IMAIZUMI A, KAWAKAMI T, MURAKAMI F, et al. Effective treatment of pruritus in atopic dermatitis using H1 antihistamines (second-generation antihistamines): changes in blood histamine and tryptase levels[J]. J Dermatol Sci, 2003, 33(1): 23-29. doi: 10.1016/S0923-1811(03)00132-4
|
[20] |
MATTERNE U, BÖHMER M M, WEISSHAAR E, et al. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema[J]. Cochrane Database Syst Rev, 2019, 1(1): CD012167. http://www.ncbi.nlm.nih.gov/pubmed/30666626
|
[21] |
HIDE M, SUZUKI T, TANAKA A, et al. Long-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: a 12-month, multicenter, open-label clinical trial[J]. J Dermatol Sci, 2019, 94 (3): 339-345. doi: 10.1016/j.jdermsci.2019.05.008
|
[22] |
CHURCH M K, MANURER M, SIMONS F E, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper[J]. Allergy, 2010, 65(4): 459-466. doi: 10.1111/j.1398-9995.2009.02325.x
|
[23] |
BOUSQUET J, KHALTAEV N, CRUZ A A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)[J]. Allergy, 2008, 63(Suppl 86): S8-S160. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.618.5776&rep=rep1&type=pdf
|
[24] |
岳志浩, 伊九, 闫泽灏, 等. 枸地氯雷他定联合复方甘草酸苷治疗亚急性湿疹疗效观察[J]. 人民军医, 2017, 60(4): 381-384. https://www.cnki.com.cn/Article/CJFDTOTAL-RMJZ201704017.htm
|
[25] |
中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组. 抗组胺药在皮肤科应用专家共识[J]. 中华皮肤科杂志, 2017, 50(6): 393-396. doi: 10.3760/cma.j.issn.0412-4030.2017.06.001
|
[26] |
SIMONS F E, SILAS P, PORTNOY J M, et al. Safety of cetirizine in infants 6 to 11 months of age: a randomized, double-blind, placebo-cintrolled study[J]. J Allergy Clin Immunol, 2003, 111(6): 1244-1248. doi: 10.1067/mai.2003.1496
|
[27] |
HAMPEL F, RATNER P, HAEUSLER J M C. Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticarial[J]. Allergy Asthma Proc, 2010, 31(4): 290-295. doi: 10.2500/aap.2010.31.3349
|
[28] |
GRIMFELD A, HOLGATE S T, CANONICA G W, et al. Prophylactic management of children at risk for recurrent upper respiratory infections: the Preventia I Study[J]. Clin Exp Allergy, 2004, 34(11): 1665-1672. doi: 10.1111/j.1365-2222.2004.02098.x
|